Affiliation:
1. Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University
Abstract
The aim of the work was a comparative experimental study of the effect of oral administration of Pentoxifylline microparticles based on PLGA, and “standard” Pentoxifylline, on the ADP-induced platelet aggregation process in rats.Materials and methods. Pentoxifylline substance (100 mg/kg) was used as a reference drug, and PLGA-based Pentoxifylline microparticles with an average dynamic radius of 175.4 nт were used as the object in study. In the experiment, male Wistar rats (m = 300–330 g), the same age group (9 months) were used. They were divided into 3 groups, each of 6 animals. The antiplatelet activity was assessed by determining the degree and rate of platelet aggregation in 1, 3, 5, 8 and 24 hours after a single oral administration of the reference drug and the object under study. Adenosine diphosphate (ADP) at the concentration of 5 μM was used as an aggregation inducer. The aggregation process was recorded using a two-channel laser platelet aggregation analyzer ALAT-2, wavelength of 0.785 μm. by determining the average conventional size of the aggregates.Results. The experiment has proved the following: PLGA-based Pentoxifylline microparticles are more effective at reducing the possibility of platelets to aggregate within 24 hours of the investigation (more than 40%) conventional to the control group value. Besides, it should be noted that according to the effectiveness of the pharmacological action during AD-induced platelet aggregation, the microparticles are commensurate with the standard sample - Pentoxifylline. The action of the microparticle object under study lasts for 24 hours, while the effect of the reference drug is over after 3 hours and then the indicators of the reference group do not differ from those of the control onel.Conclusion. When administered per os, PLGA-based Pentoxifylline microparticles prolong the pharmacological effect significantly – up to 24 hours.
Publisher
Volgograd State Medical University
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Pharmacy
Reference30 articles.
1. Dubenko OE. Sosudistye i drugie klinicheskie effekty pentoksifillina (nauchnyj obzor) [Vascular and other clinical effects of Pentoxifylline (Scientific Review)]. International Neurological Journal. 2016;1(79):107-12. Russian.
2. Voronkov AV, Pozdnyakov DI. Narushenie antitromboticheskoj funkciisosudistogo endoteliya i nekotoryh parametrov plazmennogo gemostaza na fone fokal’noj ishemii golovnogo mozga i ih korrekciya gidroksi-3,5-ditretbutil korichnoj kisloty [Disturbances of antithrombotic vascular endothelial function and some plasma hemostatic parameters at focal cerebral ischemia and their correction by 4-hydroxy-3,5-ditretbutyl cinnamic acid]. Tromboz, gemostaz i Reologia. 2017; 2(70): 73-8. DOI: 10.25555/THR.2017.2.0788. Russian.
3. Kucheryavenko AF, Spasov AA, Petrov VI, Anisimova VA. Antiagregantnaya aktivnost’ novogo proizvodnogo benzimidazola [Antiplatelet activity of the new benzimidazole derivative] Bulletin of Experimental Biology and Medicine. 2013; 12: 760-2. Russian.
4. Dhiman S, Mishra N, Sharma S. Development of PEGylated solid lipid nanoparticles of Pentoxifylline for their beneficial pharmacological potential in pathological cardiac hypertrophy. Artificial Cells, Nanomedicine, and Biotechnology. 2016; 44(8): 1901-8. DOI:10.3109/21691401.2015.1111234.
5. Jampilek J, Zaruba K, Oravec M, Kunes M, Babula P, Ulbrich P, Brezaniova I, Opatrilova R, Triska J, Suchy P. Preparation of silica nanoparticles loaded with nootropics and their in vivo permeation throughblood-brain barrier. Biomed Research Interest. 2015;2015:9. Article ID 812673. DOI:10.1155/2015/812673.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献